Genitope Corp., a biotechnology company, offers research and development of immunotherapies for the treatment of cancer in the United States. Immunotherapies are treatments that utilize the immune system to combat diseases. It develops a panel of monoclonal antibodies for the treatment of Non-Hodgkin s Lymphoma. The company was founded in 1996 and is based in Fremont, California. On December 31, 2014, Genitope Corp. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.